Effective Utilization of Combination Therapies in Pulmonary Arterial Hypertension: Working Towards Low Risk Status for Patients, featuring Evidence-Based Case Reviews

Effective Utilization of Combination Therapies in Pulmonary Arterial Hypertension: Working Towards Low Risk Status for Patients, featuring Evidence-Based Case Reviews 

On-Demand 1.5-hour Accredited Webcast

Faculty Presenters

Rebecca L. Attridge, PharmD, MSc, BCPS, BCCCP
Professor
University of the Incarnate Word Feik School of Pharmacy

Clinical Pharmacy Specialist
UT Health San Antonio, Division of Pulmonary Diseases and Critical Care Medicine
Department of Medicine
San Antonio, Texas

Neda Hanson, PharmD, MPH
Clinical Pharmacist
Generalist Central Support
Trellis Rx
Atlanta, Georgia
 
Program Description
Early diagnosis is critical for patients with pulmonary arterial hypertension (PAH) as earlier initiation of treatment with goal-oriented therapy may slow clinical deterioration. While there is no cure for PAH, several therapies are available that target the various pathways involved in its pathogenesis, and careful treatment selection can prolong and improve quality of life. Management of PAH requires a multidisciplinary team with specialized expertise and shared decision making involving regular reassessment for successful treatment and improved prognosis. The evidence-based case studies reviewed in this activity will provide managed care and specialty pharmacists opportunities to explore application of guideline recommendations and therapeutic monitoring to achieve optimal outcomes for patients with PAH. 

Target Audience: Health-system, managed care, and specialty pharmacists
Type of Activity: Application
Release date: May 18, 2021
Expiration date: May 18, 2022
Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives
At the completion of this activity, participants will be able to:

• Categorize pulmonary arterial hypertension (PAH) by WHO Functional Class and describe prognostic risk assessment tools that aid in developing treatment plans
• Distinguish between different treatment approaches to improve clinical outcomes in PAH including the use of dual and triple regimens
• Classify potential utilization management tools for existing and emerging therapies
• Express how specialty pharmacists can contribute to the multidisciplinary care team and improve quality of life for patients with PAH

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-21-212-H01-P. The activity is available for CE credit through May 18, 2022.


Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
 

---

Disclosures

Rebecca L. Attridge, PharmD, MSc, and Neda Hanson, PharmD, MPH, have no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Rose Namissa, PharmD, BCPS; Crissy Wilson; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers are used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms